Amarantus to Commence Trading on the OTCQX Marketplace Under Existing Ticker Symbol AMBS
July 13, 2015 07:05 ET
|
Amarantus BioScience Holdings, Inc.
SAN FRANCISCO and GENEVA, July 13, 2015 (GLOBE NEWSWIRE) -- Amarantus BioScience Holdings, Inc. (OTCQX:AMBS), a biotechnology company focused on developing therapeutic and diagnostic products for...
Amarantus Announces Issuance of United States Patent No. 9,066,903 Covering Proprietary Methods of Administration of Eltoprazine for the Treatment of Parkinson's Disease
June 30, 2015 08:35 ET
|
Amarantus BioScience Holdings, Inc.
SAN FRANCISCO and GENEVA, June 30, 2015 (GLOBE NEWSWIRE) -- Amarantus BioScience Holdings, Inc. (OTCQB:AMBSD), a biotechnology company focused on developing therapeutic and diagnostic products for...
Amarantus Announces Presentation of Eltoprazine Phase 1/2a Clinical Data at the 19th International Congress of Parkinson's Disease and Movement Disorders
June 15, 2015 07:05 ET
|
Amarantus BioScience Holdings, Inc.
SAN FRANCISCO and GENEVA, June 15, 2015 (GLOBE NEWSWIRE) -- Amarantus BioScience Holdings, Inc. (OTCQB:AMBSD), a biotechnology company focused on developing therapeutic and diagnostic products for...
Amarantus to Present at the BIO International Convention
June 10, 2015 08:05 ET
|
Amarantus BioScience Holdings, Inc.
SAN FRANCISCO and GENEVA, June 10, 2015 (GLOBE NEWSWIRE) -- Amarantus BioScience Holdings, Inc. (OTCQB:AMBSD), a biotechnology company focused on developing therapeutic and diagnostic products for...
Amarantus Completes Capital Restructuring in Preparation for National Exchange Listing
June 09, 2015 16:05 ET
|
Amarantus BioScience Holdings, Inc.
SAN FRANCISCO and GENEVA, June 9, 2015 (GLOBE NEWSWIRE) -- Amarantus BioScience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on developing therapeutic and diagnostic products for...
Amarantus Diagnostics Announces Acceptance of Two Late-Breaking Abstracts on LymPro Test(R) Data at the 2015 Alzheimer's Association International Conference(R)
June 09, 2015 10:58 ET
|
Amarantus BioScience Holdings, Inc.
SAN FRANCISCO and GENEVA, June 9, 2015 (GLOBE NEWSWIRE) -- Amarantus Diagnostics, a neurology-focused diagnostics company developing diagnostic tests for Multiple Sclerosis and Alzheimer's disease,...
Amarantus Opens First Clinical Trial Site and Commences Patient Enrollment for Lead Product Candidate Eltoprazine's Phase 2b Study in Parkinson's Disease Levodopa-Induced Dyskinesia
June 05, 2015 07:35 ET
|
Amarantus BioScience Holdings, Inc.
SAN FRANCISCO and GENEVA, June 5, 2015 (GLOBE NEWSWIRE) -- Amarantus BioScience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on developing diagnostics in neurology, and therapeutic...
Amarantus to Present at the Fourth Annual SeeThru Equity Microcap Investor Conference on May 28, 2015
May 26, 2015 07:05 ET
|
Amarantus BioScience Holdings, Inc.
SAN FRANCISCO and GENEVA, May 26, 2015 (GLOBE NEWSWIRE) -- Amarantus BioScience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on developing therapeutic and diagnostic products for...
Amarantus Effects Capital Restructuring in Anticipation of National Exchange Listing
May 22, 2015 07:05 ET
|
Amarantus BioScience Holdings, Inc.
SAN FRANCISCO and GENEVA, May 22, 2015 (GLOBE NEWSWIRE) -- Amarantus BioSciences Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on developing therapeutic and diagnostic products for...
Amarantus Enters Into CRO Agreement With Chiltern International to Commence Phase 2b Clinical Development of Eltoprazine in Parkinson's Disease Levodopa-Induced Dyskinesia
May 21, 2015 07:05 ET
|
Amarantus BioScience Holdings, Inc.
- Company Completes Investigator Meetings in U.S. and E.U. in Preparation for Study Launch -
- Enrollment and Dosing for 60-Patient PD-LID Study on Track to Commence 2Q 2015 -
SAN FRANCISCO and...